News & Events about Aclaris Therapeutics Inc.
Aclaris Therapeutics, Inc. (NASDAQ:ACRS Get Rating) Stock analysts at Jefferies Financial Group boosted their FY2025 earnings per share estimates for Aclaris Therapeutics in a note issued to investors on Monday, March 6th. Jefferies Financial Group analyst R. Song now expects that ...
Aclaris Therapeutics (NASDAQ:ACRS Get Rating) had its target price decreased by The Goldman Sachs Group from $25.00 to $21.00 in a report released on Tuesday , Benzinga reports. The Goldman Sachs Group currently has a buy rating on the biotechnology companys stock. Several other research analysts ...
Gainers
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch Renazorb.
read more...
Globe Newswire
2 months ago
WAYNE, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today is providing a corporate outlook for 2023. 2023 is setting up to be an incredibly ...
Eric Gulve Announces Retirement as President of BioSTL Startup Arm BioGenerator; Charlie Bolten to Take the Helm Eric Gulve Announces Retirement as President of BioSTL Startup Arm BioGenerator; Charlie Bolten to Take the Helm PR Newswire ST. LOUIS, Dec. 21, 2022 ST. LOUIS, Dec. 21, 2022...